- 1. Revealing 3-D cellular features with ophthalmic imaging
systemsLLNL-PRES-608032This work was performed under the auspices
of theU.S. Department of Energy by Lawrence LivermoreNational
Laboratory under contract DE-AC52-07NA27344.Lawrence Livermore
National Security, LLCScot S. Olivier
2. Blinding diseases can be diagnosed from fundus imagesLawrence
Livermore National Laboratory LLNL-PRES-6080322Schematic of eye
Normal fundus image Fundus image with AMD 3. Enables monitoring
changes associated with diseaseprogression, disease treatment,
normal function or agingLawrence Livermore National Laboratory
LLNL-PRES-6080323http://anatomy.iupui.edu/courses/histo_D502/D502f04/lecture.f04/Eyef04/ret.jpg
4. Enables in vivo visualization of retinal layersLawrence
Livermore National Laboratory LLNL-PRES-6080324Axial resolution as
small as 2-3 mLateral resolution >15 m too large to resolve
cells 5. Enables improved lateral resolutionLawrence Livermore
National Laboratory LLNL-PRES-6080325Lateral resolution as small as
2-3 m Use with en face imaging techniqueslimits axial resolution 6.
Enables in vivo visualization of 3-D cellular featuresLawrence
Livermore National Laboratory LLNL-PRES-6080326 Both axial
andlateral resolutionas small as 2-3 m 7. Enables reduction of
artifacts due to eye motionLawrence Livermore National Laboratory
LLNL-PRES-6080327 Scanning Laser Ophthalmoscope (SLO) capturesen
face image (in B-C plane) at video rates 8. Systems in operation at
University ofCalifornia, Davis and Indiana University UC Davis
system incorporates SLO Substantial work on image
processingsoftware at both clinical sites No substantial technical
barriers toclinical use compact designs feasibleLawrence Livermore
National Laboratory LLNL-PRES-6080328 9. In vivo visualization of
3-D cellular features requirescombination of axial and lateral
resolution unique to AOOCT technology Enables monitoring changes
associated with diseaseprogression, disease treatment, normal
function or aging Can be used by ophthalmologists for earlier
diseasediagnosis and to monitor progress during clinical
diseasetreatment, including clinical trials of new
therapiesLawrence Livermore National Laboratory LLNL-PRES-6080329
10. Genaro [email protected] Livermore National
Laboratory LLNL-PRES-608032 10